Anosmia and other SARS-CoV-2 positive test-associated symptoms, across three national, digital surveillance platforms as the COVID-19 pandemic and response unfolded : an observation study
Background: Multiple participatory surveillance platforms were developed across the world in response to the COVID-19 pandemic, providing a real-time understanding of community-wide COVID-19 epidemiology. During this time, testing criteria broadened and healthcare policies matured. We sought to test whether there were consistent associations of symptoms with SARS-CoV-2 test status across three national surveillance platforms, during periods of testing and policy changes, and whether inconsistencies could better inform our understanding and future studies as the COVID-19 pandemic progresses.
Methods: Four months (1st April 2020 to 31st July 2020) of observation through three volunteer COVID-19 digital surveillance platforms targeting communities in three countries (Israel, United Kingdom, and United States). Logistic regression of self-reported symptom on self-reported SARS-CoV-2 test status (or test access), adjusted for age and sex, in each of the study cohorts. Odds ratios over time were compared to known changes in testing policies and fluctuations in COVID-19 incidence.
Findings: Anosmia/ageusia was the strongest, most consistent symptom associated with a positive COVID-19 test, based on 658,325 tests (5% positive) from over 10 million respondents in three digital surveillance platforms using longitudinal and cross-sectional survey methodologies. During higher-incidence periods with broader testing criteria, core COVID-19 symptoms were more strongly associated with test status. Lower incidence periods had, overall, larger confidence intervals.
Interpretation: The strong association of anosmia/ageusia with self-reported SARS-CoV-2 test positivity is omnipresent, supporting its validity as a reliable COVID-19 signal, regardless of the participatory surveillance platform or testing policy. This analysis highlights that precise effect estimates, as well as an understanding of test access patterns to interpret differences, are best done only when incidence is high. These findings strongly support the need for testing access to be as open as possible both for real-time epidemiologic investigation and public health utility.
Funding: NIH, NIHR, Alzheimer's Society, Wellcome Trust.
| Errataetall: |
UpdateIn: This article has been published with doi: 10.1016/s2589-7500(21)00115-1 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2020 |
|---|---|
| Enthalten in: |
medRxiv : the preprint server for health sciences - (2020) vom: 16. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sudre, Carole H [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 30.03.2024 published: Electronic UpdateIn: This article has been published with doi: 10.1016/s2589-7500(21)00115-1 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2020.12.15.20248096 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319191281 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319191281 | ||
| 003 | DE-627 | ||
| 005 | 20240330234810.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.12.15.20248096 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1356.xml |
| 035 | |a (DE-627)NLM319191281 | ||
| 035 | |a (NLM)33354683 | ||
| 035 | |a (PII)2020.12.15.20248096 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sudre, Carole H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anosmia and other SARS-CoV-2 positive test-associated symptoms, across three national, digital surveillance platforms as the COVID-19 pandemic and response unfolded |b an observation study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: This article has been published with doi: 10.1016/s2589-7500(21)00115-1 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Background: Multiple participatory surveillance platforms were developed across the world in response to the COVID-19 pandemic, providing a real-time understanding of community-wide COVID-19 epidemiology. During this time, testing criteria broadened and healthcare policies matured. We sought to test whether there were consistent associations of symptoms with SARS-CoV-2 test status across three national surveillance platforms, during periods of testing and policy changes, and whether inconsistencies could better inform our understanding and future studies as the COVID-19 pandemic progresses | ||
| 520 | |a Methods: Four months (1st April 2020 to 31st July 2020) of observation through three volunteer COVID-19 digital surveillance platforms targeting communities in three countries (Israel, United Kingdom, and United States). Logistic regression of self-reported symptom on self-reported SARS-CoV-2 test status (or test access), adjusted for age and sex, in each of the study cohorts. Odds ratios over time were compared to known changes in testing policies and fluctuations in COVID-19 incidence | ||
| 520 | |a Findings: Anosmia/ageusia was the strongest, most consistent symptom associated with a positive COVID-19 test, based on 658,325 tests (5% positive) from over 10 million respondents in three digital surveillance platforms using longitudinal and cross-sectional survey methodologies. During higher-incidence periods with broader testing criteria, core COVID-19 symptoms were more strongly associated with test status. Lower incidence periods had, overall, larger confidence intervals | ||
| 520 | |a Interpretation: The strong association of anosmia/ageusia with self-reported SARS-CoV-2 test positivity is omnipresent, supporting its validity as a reliable COVID-19 signal, regardless of the participatory surveillance platform or testing policy. This analysis highlights that precise effect estimates, as well as an understanding of test access patterns to interpret differences, are best done only when incidence is high. These findings strongly support the need for testing access to be as open as possible both for real-time epidemiologic investigation and public health utility | ||
| 520 | |a Funding: NIH, NIHR, Alzheimer's Society, Wellcome Trust | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Keshet, Ayya |e verfasserin |4 aut | |
| 700 | 1 | |a Graham, Mark S |e verfasserin |4 aut | |
| 700 | 1 | |a Joshi, Amit D |e verfasserin |4 aut | |
| 700 | 1 | |a Shilo, Smadar |e verfasserin |4 aut | |
| 700 | 1 | |a Rossman, Hagai |e verfasserin |4 aut | |
| 700 | 1 | |a Murray, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Molteni, Erika |e verfasserin |4 aut | |
| 700 | 1 | |a Klaser, Kerstin |e verfasserin |4 aut | |
| 700 | 1 | |a Canas, Liane D |e verfasserin |4 aut | |
| 700 | 1 | |a Antonelli, Michela |e verfasserin |4 aut | |
| 700 | 1 | |a Modat, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Capdevila Pujol, Joan |e verfasserin |4 aut | |
| 700 | 1 | |a Ganesh, Sajaysurya |e verfasserin |4 aut | |
| 700 | 1 | |a Wolf, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Meir, Tomer |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Andrew T |e verfasserin |4 aut | |
| 700 | 1 | |a Steves, Claire J |e verfasserin |4 aut | |
| 700 | 1 | |a Spector, Tim D |e verfasserin |4 aut | |
| 700 | 1 | |a Brownstein, John S |e verfasserin |4 aut | |
| 700 | 1 | |a Segal, Eran |e verfasserin |4 aut | |
| 700 | 1 | |a Ourselin, Sebastien |e verfasserin |4 aut | |
| 700 | 1 | |a Astley, Christina M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t medRxiv : the preprint server for health sciences |d 2020 |g (2020) vom: 16. Dez. |w (DE-627)NLM310900166 |7 nnns |
| 773 | 1 | 8 | |g year:2020 |g day:16 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.12.15.20248096 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 16 |c 12 | ||